勃林格殷格翰拟收购病毒学企业Labor Dr. Merk Kollegen

Boehringer Ingelheim to Acquire Labor Dr. Merk Kollegen to Strengthen its Next Generation Cancer Immunology Program Boehringer Ingelheim has signed the agreement on the acquisition of all shares of Germany-based biotech company Labor Dr. Merk Kollegen Transaction expands Boehringer Ingelheim’s R D and clinical manufacturing capabilities with a site focused predominantly on ATMP (Advanced Therapy Medicinal Products)-based cancer immunology treatments Boehringer Ingelheim aims to accelerate the delivery of first-in-class immuno-oncology therapies to patients around the world December 09, 2020 04:00 AM Eastern Standard Time INGELHEIM, Germany OCHSENHAUSEN, Germany--(BUSINESS WIRE)--Boehringer Ingelheim today announced the execution of the agreement on the acquisition of Labor Dr. Merk Kollegen. The acquisition will enable Boehringer Ingelheim to further expand and accelerate its comprehensive program for the development of ATMP-based immuno-oncology therapies including the Vesicular Stomatitis Virus (VSV) with modified glycoprotein (GP) platform and cancer vaccines platforms. Labor Dr. Merk Kollegen has outstanding experience in process development, manufacturing and analytical characterization in virology besides expertise in microbiology and cell culture. Labor Dr. Merk Kollegen has already worked in close collaboration with Boehringer Ingelheim on viral-based therapy development since 2015.
（以上内容由医药魔方AI生成）